" reaffirms the significant potential for CDX-301."
"CDX-301 or rhuFlt3L is a potent cytokine that stimulates the expansion and differentiation of hematopoietic progenitor and stem cells. rhuFlt3L has demonstrated a unique capacity to increase the number of circulating dendritic cells in both laboratory and clinical studies. In addition, rhuFlt3L has shown impressive results in models of cancer, infectious diseases and inflammatory/autoimmune diseases. The clinical safety and activity of rhuFlt3L were originally demonstrated by Immunex (now Amgen) in clinical trials involving more than 150 healthy volunteers and 380 patients with cancer. Recognizing the promise of CDX-301, Celldex in-licensed the program from Amgen in 2009. Celldex's completion of this recent Phase 1 study confirms and builds upon the extensive prior clinical experience and reaffirms the significant potential for CDX-301."
Well Rays, this looks like a pretty good catalyst, it will be interesting to see how she acts today. Hey off subject....I am a huge baseball fan, Mariners because of where I live, but have been a SF Giants fan since I was 10 years old in 1965! After suffering for 45 years, never winning a WS, winning twice in the last 3 years is pretty amazing.
Ed, yes, it looks like Celldex is going to be a goldmine........., when you see the likes of Longvrts and Shareholderboar that excited about this news, IMO, it's time to pay attention.
Funny, my son and I where speaking of SanFran's accomplishments last night. You have to give respect for what they have done. And that town has a fairly good FB team as well.
Could you do me a favor and move your local BB park to Saint Pete, we could do with having what such a beautiful park here. I like the fact that you give love to the team where you live. That is a big issue here with all the Boston and NewYork fans who call Tampa home, but don't give this remarkable team called the Rays they level of support every local team needs.
"Based on the safety profile and the impressive increases observed for CD34+ stem cells and dendritic cells, we believe CDX-301 holds significant promise in both the allogeneic and autologous transplant setting, including the potential for combination with other molecules that could work in synergy with CDX-301 to further enhance the mobilization of hematopoietic stem cell populations. Published pre-clinical Flt3L studies also suggest that CDX-301 could potentially improve engraftment and reduce the risk of graph versus host disease. This may be especially important for older patients and patients who are in poor health."